Holen Sie sich die Stockscreener-App
0.2801
7.92%
-0.0242
Schlusskurs vom Vortag:
$0.3042
Offen:
$0.298
24-Stunden-Volumen:
708.40K
Relative Volume:
0.58
Marktkapitalisierung:
$25.55M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-37.68M
KGV:
-0.6147
EPS:
-0.4556
Netto-Cashflow:
$-29.82M
1W Leistung:
-6.57%
1M Leistung:
-8.64%
6M Leistung:
-62.23%
1J Leistung:
-71.24%
1-Tages-Spanne:
$0.2778
$0.298
1-Wochen-Bereich:
$0.2778
$0.348
52-Wochen-Spanne:
$0.2302
$1.05
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.2801 | 27.75M | 7.10M | -37.68M | -29.82M | -0.4556 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.81 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.49 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
Bull Run: Can Cue Biopharma Inc disrupt its industryWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
CUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Recap: Can Cue Biopharma Inc disrupt its industryPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Momentum Shift: Whats the MACD signal for OSR Holdings Inc Equity WarrantBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Stock Market Recap: Will Cue Biopharma Inc benefit from geopolitical trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
CUE Should I Buy - Intellectia AI
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Cue Biopharma sets April 13, 2026 annual meeting; February 28 deadline for shareholder proposals - TradingView
Cue’s CUE-401 well tolerated in mouse and NHP studies - BioWorld MedTech
Aug Technicals: Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Levels & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Analyzing Cue Biopharma (NASDAQ:CUE) & Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Bitget
Can Cue Biopharma Inc. outperform in the next rally2025 Earnings Surprises & Growth Focused Entry Point Reports - mfd.ru
Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail
How Cue Biopharma Inc. stock performs in rising dollar environmentWeekly Gains Report & Daily Risk Controlled Trade Plans - mfd.ru
Cue Biopharma appoints industry veteran Lucinda Warren as chief financial and business officer - marketscreener.com
Cue Biopharma (CUE) Appoints New Chief Financial and Business Of - GuruFocus
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026 - marketscreener.com
Cue Biopharma Names Lucinda Warren Chief Financial And Business Officer - Nasdaq
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Bitget
Cue Biopharma Appoints Lucinda Warren as Chief Financial and Business Officer - TradingView
Is Cue Biopharma Inc. stock attractive after correctionTreasury Yields & Short-Term High Return Ideas - mfd.ru
How Cue Biopharma Inc. stock reacts to job market dataInflation Watch & Proven Capital Preservation Tips - mfd.ru
Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Chart Watch & Daily Stock Momentum Reports - baoquankhu1.vn
What’s the RSI of Cue Biopharma Inc. stockQuarterly Growth Report & Reliable Breakout Forecasts - mfd.ru
Is Cue Biopharma Inc. stock forming a triangle pattern2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Volatility Watch: Is Cue Biopharma Inc forming a bullish divergence2025 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
CUE Stock Price, Forecast & Analysis | CUE BIOPHARMA INC (NASDAQ:CUE) - Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
Options Flow: Can Cue Biopharma Inc disrupt its industryMarket Risk Analysis & Risk Managed Investment Strategies - baoquankhu1.vn
Is Cue Biopharma Inc. (1UC) stock overpriced at current multiples2025 Trading Volume Trends & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Is Cue Biopharma Inc benefiting from interest rate changesInsider Buying & Daily Stock Momentum Reports - baoquankhu1.vn
Cue Biopharma (NASDAQ:CUE) Shares Up 9% – Should You Buy? - Defense World
Activity Recap: Whats the profit margin of Cue Biopharma IncJuly 2025 Short Interest & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Can Cue Biopharma Inc be recession proofJuly 2025 Snapshot & Daily Growth Stock Investment Tips - baoquankhu1.vn
Cue Biopharma launches proposed public offering of shares and warrants - MSN
Can Cue Biopharma Inc. stock outperform in 2025 bull marketWeekly Investment Recap & AI Driven Price Forecasts - Улправда
How sustainable is Cue Biopharma Inc. stock dividend payout2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Why Cue Biopharma Inc. stock is trending among retail tradersStock Surge & Verified Momentum Stock Ideas - Улправда
What sentiment indicators say about Cue Biopharma Inc. stock2025 Pullback Review & Reliable Momentum Entry Alerts - Улправда
Aug Big Picture: Why Cue Biopharma Inc. stock remains resilient2025 Top Gainers & Consistent Return Strategy Ideas - Улправда
Why Cue Biopharma Inc. stock remains resilientJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - Улправда
Will Cue Biopharma Inc. stock see insider buyingStop Loss Placement Tips & Small Entry Cost Investments - Улправда
Institution Moves: Will Cue Biopharma Inc 1UC stock benefit from mergersTrade Risk Assessment & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):